19
Participants
Start Date
November 30, 2005
Primary Completion Date
February 28, 2009
Study Completion Date
May 31, 2010
Zevalin-BuCyE
rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
Asan Medical Center, Departement of Internal Medicine, Division of Oncology, Seoul
Lead Sponsor
Collaborators (1)
Schering-Plough
INDUSTRY
Asan Medical Center
OTHER